Research Analysts Set Expectations for PTCT FY2026 Earnings

PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Stock analysts at Cantor Fitzgerald decreased their FY2026 earnings per share estimates for PTC Therapeutics in a note issued to investors on Monday, June 30th. Cantor Fitzgerald analyst K. Kluska now expects that the biopharmaceutical company will earn ($3.22) per share for the year, down from their previous estimate of ($2.69). Cantor Fitzgerald has a "Overweight" rating and a $112.00 price objective on the stock. The consensus estimate for PTC Therapeutics' current full-year earnings is ($4.52) per share.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $10.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $9.19. The firm had revenue of $1.18 billion during the quarter, compared to the consensus estimate of $437.16 million. PTC Therapeutics had a negative return on equity of 78.56% and a net margin of 33.56%. The company's quarterly revenue was down 9.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.20) EPS.

Several other research analysts also recently weighed in on PTCT. Citigroup raised shares of PTC Therapeutics from a "sell" rating to a "neutral" rating and cut their target price for the company from $50.00 to $40.00 in a research note on Wednesday, May 7th. Wall Street Zen downgraded shares of PTC Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 16th. Barclays lowered their target price on shares of PTC Therapeutics from $56.00 to $42.00 and set an "equal weight" rating for the company in a research note on Thursday, May 8th. Truist Financial started coverage on shares of PTC Therapeutics in a research note on Tuesday, June 17th. They set a "buy" rating and a $80.00 price target on the stock. Finally, Robert W. Baird lowered their price objective on shares of PTC Therapeutics from $70.00 to $66.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, PTC Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $65.00.

PTC Therapeutics Trading Down 0.8%

Shares of NASDAQ PTCT traded down $0.38 during trading on Wednesday, reaching $48.77. The company had a trading volume of 307,079 shares, compared to its average volume of 862,349. PTC Therapeutics has a twelve month low of $29.02 and a twelve month high of $58.38. The stock has a 50-day moving average price of $48.22 and a two-hundred day moving average price of $48.27. The stock has a market capitalization of $3.87 billion, a PE ratio of 7.49 and a beta of 0.50.

Insider Activity

In other news, CEO Matthew B. Klein sold 2,804 shares of PTC Therapeutics stock in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $48.74, for a total value of $136,666.96. Following the completion of the transaction, the chief executive officer owned 273,234 shares in the company, valued at approximately $13,317,425.16. This trade represents a 1.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Mark Elliott Boulding sold 1,929 shares of the business's stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $46.18, for a total value of $89,081.22. Following the completion of the sale, the vice president owned 103,901 shares of the company's stock, valued at $4,798,148.18. This trade represents a 1.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,616 shares of company stock worth $266,384 in the last ninety days. Corporate insiders own 5.50% of the company's stock.

Hedge Funds Weigh In On PTC Therapeutics

A number of hedge funds have recently added to or reduced their stakes in PTCT. Smartleaf Asset Management LLC raised its holdings in shares of PTC Therapeutics by 78.7% during the fourth quarter. Smartleaf Asset Management LLC now owns 613 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 270 shares during the period. Sterling Capital Management LLC grew its position in shares of PTC Therapeutics by 424.4% during the 4th quarter. Sterling Capital Management LLC now owns 645 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 522 shares during the last quarter. Quantbot Technologies LP raised its stake in PTC Therapeutics by 545.5% during the first quarter. Quantbot Technologies LP now owns 652 shares of the biopharmaceutical company's stock worth $33,000 after acquiring an additional 551 shares during the period. PNC Financial Services Group Inc. lifted its holdings in PTC Therapeutics by 84.2% in the first quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company's stock worth $36,000 after acquiring an additional 320 shares during the last quarter. Finally, GAMMA Investing LLC boosted its stake in PTC Therapeutics by 86.3% in the first quarter. GAMMA Investing LLC now owns 952 shares of the biopharmaceutical company's stock valued at $49,000 after acquiring an additional 441 shares during the period.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.